What is Tvardi Therapeutics, Inc.'s earnings per share (EPS)?

Tvardi Therapeutics, Inc. (TVRD) reported diluted earnings per share of -$3.26 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Tvardi Therapeutics, Inc. (TVRD) Financials

TVRD

FY2025 annual

Revenue Not reported for FY2025

Net Income -$18.2M +38.1% YoY

EPS (Diluted) -$3.26 YoY not available

Operating Cash Flow -$23.5M -28.4% YoY

Market Cap $23.5M as of Sep 15, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 2.8x on $8.4M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TVRD SEC filings page.

This page shows Tvardi Therapeutics, Inc. (TVRD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TVRD FY2025 2026-08-30

Development-stage spending drives Tvardi’s losses, while financing flows rather than operations reshape the balance sheet.

In FY2025, operating cash flow was -$23.5M against a net loss of -$18.2M, so accounting losses understated the cash requirement. Financing cash flow of $22.7M alongside investing cash flow of -$10.1M indicates that funding activity, not internal cash generation, supported the year’s cash needs.

R&D was the dominant expense engine at $18.0M in FY2025 versus SG&A of $8.7M, consistent with a business still prioritizing development over commercial administration. R&D fell to $18.0M from $23.7M in FY2024 while the operating loss also narrowed; the improvement is consistent with a smaller cost base, not demonstrated commercial scale.

Equity moved from -$91.1M in FY2024 to $20.9M in FY2025; that reversal reflects a capital-structure change, not operating profitability. A current ratio of 2.9x and liquidity measure of 15.7 months of reported outflow indicate that short-term resources exceeded current obligations at year-end.

Financial Health Signals

Financial health score not available

Tvardi Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Tvardi Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Tvardi Therapeutics, Inc. reported a net loss of $18.2M while operations used $23.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$6.6M

YoY+25.3%

QoQ+6.0%

Tvardi Therapeutics, Inc.'s EBITDA was -$6.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.3% from the same quarter a year earlier. Against the prior quarter it is up 6.0%.

Net Income

-$6.5M

YoY-255.0%

QoQ+5.1%

Tvardi Therapeutics, Inc. reported -$6.5M in net income in Q2 2026. This represents a decrease of 255.0% from the same quarter a year earlier. Against the prior quarter it is up 5.1%.

EPS (Diluted)

-$0.69

YoY+31.0%

QoQ+5.5%

Tvardi Therapeutics, Inc. earned -$0.69 per diluted share (EPS) in Q2 2026. This represents an increase of 31.0% from the same quarter a year earlier. Against the prior quarter it is up 5.5%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$15.8M

YoY-23.6%

QoQ-20.6%

5Y CAGR-6.7%

10Y CAGR+16.1%

Tvardi Therapeutics, Inc. held $15.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

13M

YoY+42.2%

QoQ+42.2%

5Y CAGR-23.3%

10Y CAGR-6.9%

Tvardi Therapeutics, Inc. had 13M shares outstanding in Q2 2026. This represents an increase of 42.2% from the same quarter a year earlier. Against the prior quarter it is up 42.2%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-77.0%

YoY-89.7pp

QoQ-30.1pp

Tvardi Therapeutics, Inc.'s ROE was -77.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 89.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 30.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$4.0M

YoY-31.1%

QoQ-18.5%

Tvardi Therapeutics, Inc. invested $4.0M in research and development in Q2 2026. This represents a decrease of 31.1% from the same quarter a year earlier. Against the prior quarter it is down 18.5%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

TVRD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TVRD quarterly income statement

Metric	TTM	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	N/A	N/A	$7.1M-66.0%	$21.0M-49.9%	$41.9M+81.8%	$23.0M-83.0%	$135.1M+579.3%	$19.9M+47.6%	$13.5M+1378.5%	$911K+959.3%	$86K-97.7%	$3.8M+19.7%	$3.2M-73.4%	$12.0M+905.4%	$1.2M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$23.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$18.0M-23.8%	$23.6M-78.2%	$108.5M+18.1%	$91.9M+11.1%	$82.7M-23.3%	$107.9M-5.2%	$113.8M+50.7%	$75.5M+55.7%	$48.5M-1.5%	$49.3M+132.1%	$21.2M+40.8%	$15.1M+73.5%	$8.7M+88.9%	$4.6M
SG&A Expenses	N/A	$8.7M+96.0%	$4.5M-84.0%	$27.8M-8.2%	$30.3M+2.9%	$29.4M+34.6%	$21.8M+23.1%	$17.7M+15.8%	$15.3M+29.0%	$11.9M+28.6%	$9.2M+18.8%	$7.8M+25.7%	$6.2M+75.8%	$3.5M+24.3%	$2.8M
Operating Income	N/A	-$26.7M+4.8%	-$28.1M+76.9%	-$121.5M-38.8%	-$87.5M+1.7%	-$89.1M-1754.3%	$5.4M+104.8%	-$111.7M-44.3%	-$77.4M-30.1%	-$59.5M-1.9%	-$58.4M-131.9%	-$25.2M-39.4%	-$18.1M-7525.3%	-$237K+96.2%	-$6.2M
EBITDA	N/A	-$26.7M+4.9%	-$28.0M+76.9%	-$121.2M-38.9%	-$87.3M+1.7%	-$88.8M-1688.0%	$5.6M+105.0%	-$111.5M-44.8%	-$77.0M-30.6%	-$59.0M-3.6%	-$56.9M-133.8%	-$24.3M-40.8%	-$17.3M-3232.1%	$552K+110.6%	-$5.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3.8M+5590.9%	$66K
Income Tax	N/A	$0	$0	$0	$0	$0+100.0%	-$691K+15.3%	-$816K-109.8%	-$389K-90.7%	-$204K+56.4%	-$468K-17.9%	-$397K-97.5%	-$201K-570.0%	-$30K+3.2%	-$31K
Net Income	N/A	-$18.2M+38.1%	-$29.4M-148.1%	-$11.8M+86.1%	-$85.5M+3.4%	-$88.4M-1151.6%	$8.4M+107.9%	-$106.4M-43.7%	-$74.0M-27.3%	-$58.1M-1.5%	-$57.3M-132.0%	-$24.7M-39.1%	-$17.7M-347.8%	-$4.0M+36.8%	-$6.3M
EPS (Basic)	N/A	-$2.46+78.5%	-$11.42+56.5%	-$26.26-37.3%	-$19.12-998.9%	-$1.74-1066.7%	$0.18+107.2%	-$2.49-20.9%	-$2.06	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$2.77	-$3.26	-$11.42	-$26.26	-$19.12	-$1.74-1066.7%	$0.18+107.2%	-$2.49-20.9%	-$2.06	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	8M	3M	5M	4M	51M+5.9%	48M+12.3%	43M+18.9%	36M+15.0%	31M+14.4%	27M+10.8%	25M+17.4%	21M+407.3%	4M+25.2%	3M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	N/A	N/A	$2.6M+20.3%	$1.5M-51.6%	$2.6M-47.5%
R&D Expenses	$4.0M-31.1%	$4.9M+57.9%	N/A	$3.6M-24.9%	$5.8M-11.1%	$3.1M-85.8%	-$9.6M-66.1%	$4.8M-81.2%
SG&A Expenses	$2.6M-14.2%	$2.1M+72.2%	N/A	$2.3M+165.0%	$3.1M+371.2%	$1.2M-81.8%	-$3.9M-159.0%	$881K-87.0%
Operating Income	-$6.6M+25.3%	-$7.1M-61.9%	N/A	-$5.9M-4.6%	-$8.9M-23.5%	-$4.4M+85.3%	$14.4M+144.2%	-$5.7M+80.4%
EBITDA	-$6.6M+25.3%	-$7.0M-62.3%	N/A	-$5.9M-4.6%	-$8.8M-23.3%	-$4.3M+85.4%	$14.4M+144.4%	-$5.7M+80.4%
Interest Expense	N/A	N/A	N/A	N/A	N/A	$558K	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Net Income	-$6.5M-255.0%	-$6.8M+29.0%	N/A	-$5.5M-0.3%	$4.2M+159.7%	-$9.6M-128.0%	-$12.7M-117.1%	-$5.5M+80.3%
EPS (Basic)	-$0.69-235.3%	-$0.73+80.4%	-$0.84+94.2%	-$0.59+72.4%	$0.51+118.8%	-$3.72+81.6%	-$14.38-2296.7%	-$2.14-311.5%
EPS (Diluted)	-$0.69+31.0%	-$0.73	-$0.76	-$0.59	-$1.00	-$3.72	-$14.38	-$2.14
Diluted Shares (Avg)	9M+11.0%	9M	N/A	9M	8M	3M	N/A	3M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

TVRD Balance Sheet

TVRD quarterly balance sheet

Metric	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$32.1M-8.9%	$35.2M-72.0%	$125.8M-30.9%	$182.2M-26.2%	$247.1M-8.9%	$271.2M+16.4%	$233.0M+22.1%	$190.8M+96.7%	$97.0M+52.0%	$63.8M-42.4%	$110.9M+98.3%	$55.9M+209.3%	$18.1M	N/A
Current Assets	$31.5M-0.5%	$31.7M-72.7%	$116.2M-31.2%	$168.9M-2.5%	$173.3M-11.2%	$195.1M+17.8%	$165.7M-1.5%	$168.1M+76.9%	$95.1M+54.7%	$61.4M-43.6%	$108.9M+105.0%	$53.1M+265.1%	$14.6M	N/A
Cash & Equivalents	$20.7M-34.4%	$31.6M-38.9%	$51.8M-18.8%	$63.7M+373.8%	$13.5M-57.5%	$31.7M+73.1%	$18.3M+21.4%	$15.1M+60.6%	$9.4M-22.4%	$12.1M-19.9%	$15.1M-71.3%	$52.7M+326.2%	$12.4M+1006.3%	$1.1M
Short-Term Investments	$10.1M	$0-100.0%	$49.0M-40.0%	$81.7M-46.8%	$153.6M+2.9%	$149.2M+9.2%	$136.7M-6.6%	$146.3M+75.9%	$83.2M+80.1%	$46.2M-49.6%	$91.6M	$0	$0	$0
Inventory	N/A	$900K-68.1%	$2.8M+18.4%	$2.4M-7.8%	$2.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$407K-85.3%	$2.8M-15.2%	$3.3M	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0-100.0%	$11.3M-83.7%	$69.8M-1.1%	$70.6M+11.7%	$63.2M+195.2%	$21.4M	$0	$0	$0	$0	$0	$0
Total Liabilities	$11.1M-91.2%	$126.3M-32.8%	$187.9M+701.0%	$23.5M+20.1%	$19.5M-11.8%	$22.2M-52.1%	$46.2M-19.1%	$57.2M+459.4%	$10.2M-22.0%	$13.1M+123.9%	$5.9M+37.0%	$4.3M-94.1%	$72.2M	N/A
Current Liabilities	$11.0M+6.5%	$10.4M-59.5%	$25.6M+9.1%	$23.5M+33.2%	$17.6M-4.7%	$18.5M-56.9%	$42.9M+6.0%	$40.4M+375.5%	$8.5M-26.2%	$11.5M+118.9%	$5.3M+55.0%	$3.4M-37.5%	$5.4M	N/A
Non-Current Liabilities	$85K-99.9%	$116.0M-28.6%	$162.3M	$0-100.0%	$1.9M-47.8%	$3.7M+9.6%	$3.4M-80.0%	$16.7M+874.7%	$1.7M+9.4%	$1.6M+168.4%	$585K-33.1%	$874K-98.7%	$66.7M	N/A
Total Equity	$20.9M+123.0%	-$91.1M-46.8%	-$62.1M-139.1%	$158.8M-30.2%	$227.5M-8.6%	$249.0M+33.4%	$186.7M+39.7%	$133.6M+54.0%	$86.8M+71.1%	$50.7M-51.7%	$105.0M+103.3%	$51.7M+195.5%	-$54.1M+7.0%	-$58.1M
Retained Earnings	-$110.5M-19.7%	-$92.2M+86.5%	-$684.7M-20.9%	-$566.2M-17.8%	-$480.8M-22.5%	-$392.3M+2.1%	-$400.7M-36.1%	-$294.4M-33.6%	-$220.3M-35.9%	-$162.2M-54.6%	-$104.9M-30.8%	-$80.2M-28.4%	-$62.5M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$17.5M-60.0%	$25.8M-33.7%	$32.1M-8.9%	$39.0M-24.0%	$43.8M-39.7%	$38.9M-56.8%	$35.2M-72.0%	$51.3M-55.5%
Current Assets	$17.1M-60.4%	$25.3M	$31.5M-0.5%	$38.4M-19.8%	$43.1M-32.5%	N/A	$31.7M-72.7%	$47.9M-52.4%
Cash & Equivalents	$15.8M-23.6%	$19.9M-42.0%	$20.7M-34.4%	$21.4M-42.2%	$20.6M-58.1%	$34.2M-27.2%	$31.6M-38.9%	$37.1M-41.1%
Short-Term Investments	$0-100.0%	$5.1M	$10.1M	$15.0M+202.4%	$20.3M+175.7%	$0-100.0%	$0-100.0%	$5.0M-68.2%
Inventory	N/A	N/A	N/A	N/A	N/A	$900K-67.2%	$900K-68.1%	$625K-80.9%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$1.2M-28.5%	$407K-85.3%	$435K-87.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%
Total Liabilities	$9.1M-15.6%	$11.3M-91.9%	$11.1M-91.2%	$11.2M-91.4%	$10.8M-92.6%	$139.6M-10.7%	$126.3M-32.8%	$129.8M+337.2%
Current Liabilities	$9.1M-14.7%	$11.3M+838.9%	$11.0M+6.5%	$11.0M+10.0%	$10.7M-23.2%	$1.2M-92.1%	$10.4M-59.5%	$10.0M-56.1%
Non-Current Liabilities	$22K-84.8%	$54K-100.0%	$85K-99.9%	$115K-99.9%	$145K-99.9%	$138.4M-2.0%	$116.0M-28.6%	$119.8M+1657.8%
Total Equity	$8.4M-74.5%	$14.5M+114.4%	$20.9M+123.0%	$27.9M+135.5%	$32.9M+145.1%	-$100.6M-52.1%	-$91.1M-46.8%	-$78.5M-191.7%
Retained Earnings	-$123.7M-26.7%	-$117.3M+84.6%	-$110.5M-19.7%	-$103.2M+86.2%	-$97.6M+86.7%	-$760.5M-6.3%	-$92.2M+86.5%	-$747.9M-14.6%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

TVRD Cash Flow Statement

TVRD quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$25.0M	-$23.5M-28.4%	-$18.3M+80.1%	-$92.1M-17.0%	-$78.7M-31.0%	-$60.1M-995.1%	-$5.5M+95.0%	-$109.2M-389.8%	-$22.3M+59.3%	-$54.8M-15.7%	-$47.4M-120.6%	-$21.5M-21.7%	-$17.6M-723.6%	$2.8M+146.9%	-$6.0M
Depreciation & Amortization	N/A	$95K0.0%	$95K-63.3%	$259K+4.4%	$248K0.0%	$248K+18.7%	$209K+5.6%	$198K-46.5%	$370K-25.3%	$495K-66.2%	$1.5M+74.6%	$839K+7.2%	$783K-0.8%	$789K-22.7%	$1.0M
Stock-Based Compensation	N/A	$1.4M+338.6%	$319K-97.7%	$13.7M-22.6%	$17.7M-14.7%	$20.8M+40.1%	$14.8M+18.0%	$12.6M+32.6%	$9.5M+63.6%	$5.8M+106.9%	$2.8M+11.4%	$2.5M+83.4%	$1.4M+1014.6%	$123K+101.6%	$61K
Capital Expenditures	N/A	N/A	$1.0M-56.0%	$2.4M+5423.3%	$43K+10.3%	$39K-88.8%	$349K+1838.9%	$18K-75.3%	$73K+25.9%	$58K-91.9%	$717K+3485.0%	$20K-52.4%	$42K+740.0%	$5K	N/A
Free Cash Flow	N/A	N/A	-$19.4M+79.5%	-$94.5M-19.9%	-$78.8M-31.0%	-$60.1M-930.3%	-$5.8M+94.7%	-$109.2M-388.3%	-$22.4M+59.2%	-$54.9M-14.1%	-$48.1M-123.7%	-$21.5M-21.6%	-$17.7M-726.2%	$2.8M	N/A
Investing Cash Flow	$20.5M	-$10.1M-120.7%	$48.7M+12.1%	$43.5M-66.2%	$128.7M+2809.1%	-$4.8M+76.6%	-$20.3M+33.6%	-$30.5M+63.2%	-$82.8M-126.9%	-$36.5M-181.1%	$45.0M	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	$22.7M-15.9%	$27.0M-29.2%	$38.2M+12167.2%	$311K-99.3%	$46.6M+19.1%	$39.1M-72.6%	$142.6M+28.7%	$110.8M+26.0%	$87.9M+71382.1%	$123K	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$9.2M-57.3%	-$5.9M+23.8%	-$5.7M-17.6%	-$4.3M+36.0%	-$5.9M-124.8%	-$7.7M+74.8%	-$4.8M+72.2%	-$6.7M+66.1%
Depreciation & Amortization	$23K0.0%	$24K0.0%	$24K0.0%	$24K0.0%	$23K+360.0%	$24K-42.9%	$24K-70.7%	$24K-59.3%
Stock-Based Compensation	$335K-46.6%	$370K+362.5%	N/A	$339K+323.8%	$627K+693.7%	$80K-97.6%	N/A	$80K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$4.8M+75.1%	-$6.7M
Investing Cash Flow	$5.1M+153.8%	$5.0M+145.7%	$5.0M0.0%	$5.3M+114.0%	-$9.6M-162.5%	-$10.9M-141.9%	$5.0M+116.6%	$2.5M-89.2%
Financing Cash Flow	N/A	N/A	$1K-100.0%	-$322K-2200.0%	$24.6M+3469.1%	-$1.6M-134.0%	$27.0M-26.0%	-$14K-101.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TVRD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TVRD quarterly financial ratios

Metric	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	N/A	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-393.8%	-579.4%	-209.1%	-386.9%	4.0%	-561.6%	-574.5%	-6529.6%	-67907.0%	-662.3%	-568.8%	-2.0%	-524.0%
Net Margin	N/A	-411.9%	-56.5%	-204.2%	-384.1%	6.2%	-534.9%	-549.5%	-6380.4%	-66604.7%	-649.2%	-558.5%	-33.1%	-527.0%
Return on Equity	-86.9%	N/A	N/A	-53.8%-15.0pp	-38.9%-42.3pp	3.4%+60.3pp	-57.0%-1.6pp	-55.4%+11.6pp	-67.0%+45.9pp	-112.9%-89.4pp	-23.5%+10.9pp	-34.4%	N/A	N/A
Return on Assets	-56.8%+26.8pp	-83.5%-74.1pp	-9.4%+37.5pp	-46.9%-11.1pp	-35.8%-38.9pp	3.1%+48.8pp	-45.7%-6.9pp	-38.8%+21.1pp	-59.9%+29.8pp	-89.7%-67.5pp	-22.3%+9.5pp	-31.7%-9.8pp	-21.9%	N/A
Current Ratio	2.86-0.2x	3.06-1.5x	4.54-2.7x	7.20-2.6x	9.84-0.7x	10.55+6.7x	3.86-0.3x	4.16-7.0x	11.18+5.8x	5.33-15.4x	20.68+5.0x	15.64+13.0x	2.68	N/A
Debt-to-Equity	0.53	N/A	N/A	0.15+0.1x	0.090.0x	0.09-0.2x	0.25-0.2x	0.43+0.3x	0.12-0.1x	0.26+0.2x	0.060.0x	0.08	N/A	N/A
Asset Turnover	N/A	0.200.0x	0.17-0.1x	0.23+0.1x	0.09-0.4x	0.50+0.4x	0.090.0x	0.07+0.1x	0.010.0x	0.000.0x	0.030.0x	0.06-0.6x	0.66	N/A
FCF Margin	N/A	-271.1%	-450.5%	-188.2%	-261.1%	-4.3%	-549.4%	-166.1%	-6024.7%	-55927.9%	-565.3%	-556.6%	23.6%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	N/A	N/A	N/A	N/A	-169.5%	990.8%	-222.1%
Net Margin	N/A	N/A	N/A	N/A	N/A	-372.9%	-873.5%	-215.7%
Return on Equity	-77.0%-89.7pp	-46.9%	N/A	-19.8%	12.7%	N/A	N/A	N/A
Return on Assets	-36.9%-46.4pp	-26.4%-1.8pp	N/A	-14.2%-3.4pp	9.5%+19.1pp	-24.6%-19.9pp	-36.1%-95.2pp	-10.7%+13.6pp
Current Ratio	1.87-2.2x	2.25	2.86-0.2x	3.48-1.3x	4.04-0.6x	N/A	3.06-1.5x	4.77+0.4x
Debt-to-Equity	1.09+0.8x	0.78	0.53	0.40	0.33	N/A	N/A	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	0.070.0x	0.040.0x	0.050.0x
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-332.2%	-260.4%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Tvardi Therapeutics, Inc. TVRD	FY2025	N/A	-$18.2M	N/A	$23.5M	—
LB Pharmaceuticals Inc LBRX	FY2025	N/A	-$25.2M	N/A	$1.4B	—
Abeona Therapeutics Inc. ABEO	FY2025	$5.8M	-$71.2M	N/A	$310.5M	52/100
CytomX Therapeutics, Inc. CTMX	FY2025	$76.2M	-$17.4M	-22.8%	$697.3M	49/100
Immuneering Corporation IMRX	FY2025	N/A	-$56.0M	N/A	$280.1M	—
Design Therapeutics, Inc. DSGN	FY2025	$0	-$69.8M	N/A	$846.1M	—

Where Tvardi Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Tvardi Therapeutics, Inc. profitable?

No, Tvardi Therapeutics, Inc. (TVRD) reported a net income of -$18.2M in fiscal year 2025.

What is Tvardi Therapeutics, Inc.'s EBITDA?

Tvardi Therapeutics, Inc. (TVRD) had EBITDA of -$26.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Tvardi Therapeutics, Inc.'s return on equity (ROE)?

Tvardi Therapeutics, Inc. (TVRD) has a return on equity of -86.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Tvardi Therapeutics, Inc.'s operating cash flow?

Tvardi Therapeutics, Inc. (TVRD) recorded an outflow of $23.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Tvardi Therapeutics, Inc.'s total assets?

Tvardi Therapeutics, Inc. (TVRD) had $32.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Tvardi Therapeutics, Inc. spend on research and development?

Tvardi Therapeutics, Inc. (TVRD) invested $18.0M in research and development during fiscal year 2025.

How many shares does Tvardi Therapeutics, Inc. have outstanding?

Tvardi Therapeutics, Inc. (TVRD) had 9M shares outstanding as of fiscal year 2025.

What is Tvardi Therapeutics, Inc.'s current ratio?

Tvardi Therapeutics, Inc. (TVRD) had a current ratio of 2.86 as of fiscal year 2025, which is generally considered healthy.

What is Tvardi Therapeutics, Inc.'s debt-to-equity ratio?

Tvardi Therapeutics, Inc. (TVRD) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Tvardi Therapeutics, Inc.'s return on assets (ROA)?

Tvardi Therapeutics, Inc. (TVRD) had a return on assets of -56.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Tvardi Therapeutics, Inc.'s P/E ratio?

Tvardi Therapeutics, Inc. (TVRD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $23.5M as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Tvardi Therapeutics, Inc.'s price-to-sales ratio?

Tvardi Therapeutics, Inc. (TVRD) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $23.5M as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Tvardi Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Tvardi Therapeutics, Inc. (TVRD) held $30.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.5M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Tvardi Therapeutics, Inc.'s Piotroski F-Score?

Tvardi Therapeutics, Inc. (TVRD) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Tvardi Therapeutics, Inc.'s earnings high quality?

Tvardi Therapeutics, Inc. (TVRD) reported a net loss of $18.2M while operations used $23.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.